(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 558 779 |
平均出来高 | 2.52M |
時価総額 | 242.38M |
EPS | $0 ( 2024-03-04 ) |
次の収益日 | ( $-0.200 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.910 |
ATR14 | $0.00300 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Deep Track Capital, Lp | Buy | 0 | Common Stock |
2024-02-20 | Zalevsky Jonathan | Sell | 9 014 | Common Stock |
2024-02-20 | Wilson Mark Andrew | Sell | 7 606 | Common Stock |
2024-02-20 | Robin Howard W | Sell | 20 033 | Common Stock |
2023-12-13 | Zalevsky Jonathan | Buy | 250 000 | Stock Option |
INSIDER POWER |
---|
84.96 |
Last 97 transactions |
Buy: 6 976 063 | Sell: 637 451 |
ボリューム 相関
Nektar Therapeutics 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Nektar Therapeutics 相関 - 通貨/商品
Nektar Therapeutics 財務諸表
Annual | 2023 |
収益: | $90.12M |
総利益: | $53.48M (59.34 %) |
EPS: | $-1.450 |
FY | 2023 |
収益: | $90.12M |
総利益: | $53.48M (59.34 %) |
EPS: | $-1.450 |
FY | 2022 |
収益: | $92.06M |
総利益: | $70.42M (76.50 %) |
EPS: | $-1.970 |
FY | 2021 |
収益: | $101.91M |
総利益: | $77.01M (75.57 %) |
EPS: | $-2.86 |
Financial Reports:
No articles found.
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。